CCM
Catalio Capital Management Portfolio holdings
AUM
$477M
This Quarter Return
+7.86%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$477M
AUM Growth
+$477M
(+18%)
Cap. Flow
+$48.4M
Cap. Flow
% of AUM
10.15%
Top 10 Holdings %
Top 10 Hldgs %
62.53%
Holding
48
New
12
Increased
8
Reduced
14
Closed
7
Top Buys
| 1 |
Gilead Sciences
GILD
|
$25.2M |
| 2 |
Boston Scientific
BSX
|
$24.6M |
| 3 |
Eli Lilly
LLY
|
$23.6M |
| 4 |
Soleno Therapeutics
SLNO
|
$20.9M |
| 5 |
Teva Pharmaceuticals
TEVA
|
$19.6M |
Top Sells
| 1 |
Becton Dickinson
BDX
|
$46.7M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
$33.5M |
| 3 |
Veracyte
VCYT
|
$22.6M |
| 4 |
LivaNova
LIVN
|
$15M |
| 5 |
Inspire Medical Systems
INSP
|
$13.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Eli Lilly
LLY
$657B
| $42M | 8.81% | 53,916 +30,234 | +128% | +$23.6M |
|
2
BridgeBio Pharma
BBIO
$9.89B
| $40.1M | 8.4% | 927,711 -35,172 | -4% | -$1.52M |
|
|
3
Soleno Therapeutics
SLNO
$3.6B
| $34.3M | 7.2% | 409,944 +248,982 | +155% | +$20.9M |
|
4
Ascendis Pharma
ASND
$11.8B
| $31.1M | 6.51% | 179,926 -15,597 | -8% | -$2.69M |
|
5
Intuitive Surgical
ISRG
$170B
| $30.8M | 6.46% | 56,674 +20,175 | +55% | +$11M |
|
6
Edwards Lifesciences
EW
$47.8B
| $30.6M | 6.41% | 390,932 -44,656 | -10% | -$3.49M |
|
|
7
Gilead Sciences
GILD
$140B
| $25.2M | 5.27% | +226,875 | New | +$25.2M |
|
|
8
Boston Scientific
BSX
$156B
| $24.6M | 5.16% | +229,046 | New | +$24.6M |
|
9
Cytokinetics
CYTK
$4.23B
| $19.9M | 4.17% | 601,439 +15,627 | +3% | +$516K |
|
10
Syndax Pharmaceuticals
SNDX
$1.41B
| $19.7M | 4.13% | 2,104,512 +370,811 | +21% | +$3.47M |
|
|
11
Teva Pharmaceuticals
TEVA
$21.1B
| $19.6M | 4.11% | +1,170,372 | New | +$19.6M |
|
12
Corcept Therapeutics
CORT
$7.35B
| $17.6M | 3.68% | +239,125 | New | +$17.6M |
|
13
Natera
NTRA
$23.1B
| $16.4M | 3.45% | +97,297 | New | +$16.4M |
|
14
Adaptive Biotechnologies
ADPT
$2.01B
| $16.3M | 3.41% | 1,396,445 +784,806 | +128% | +$9.14M |
|
15
Dianthus Therapeutics
DNTH
$759M
| $13.9M | 2.92% | 746,527 -16,944 | -2% | -$316K |
|
16
Structure Therapeutics
GPCR
$1.11B
| $13.9M | 2.92% | 670,575 -34,289 | -5% | -$711K |
|
17
ADMA Biologics
ADMA
$4.12B
| $10.4M | 2.18% | +569,704 | New | +$10.4M |
|
18
Halozyme
HALO
$8.56B
| $9.96M | 2.09% | +191,529 | New | +$9.96M |
|
19
Ultragenyx Pharmaceutical
RARE
$2.89B
| $7.76M | 1.63% | +213,402 | New | +$7.76M |
|
20
MoonLake Immunotherapeutics
MLTX
$3.54B
| $7.67M | 1.61% | 162,596 +47,980 | +42% | +$2.26M |
|
21
Phathom Pharmaceuticals
PHAT
$864M
| $6.45M | 1.35% | +672,290 | New | +$6.45M |
|
22
uniQure
QURE
$896M
| $5.82M | 1.22% | 417,443 -412,882 | -50% | -$5.76M |
|
23
GeneDx Holdings
WGS
$3.72B
| $5.68M | 1.19% | +61,507 | New | +$5.68M |
|
24
Protara Therapeutics
TARA
$120M
| $4.93M | 1.03% | 1,626,370 +537,679 | +49% | +$1.63M |
|
25
Outset Medical
OM
$247M
| $3.2M | 0.67% | 166,666 | – | – |
|